Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 165

Sort by

Sort Order Select

Journal Articles

Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature

Salma B. Abdelbaky, Brian Giacopelli, Kari G. Rabe, Kyoko Yamaguchi, Yue-Zhong Wu, Huihuang Yan, Tait D. Shanafelt, Sameer A. Parikh, Wei Ding, Paul J. Hampel, Sochilt Brown, James R. Cerhan, Celine M. Vachon, Neil E. Kay, Curtis A. Hanson, Alexander S. Parker, Esteban Braggio, Susan L. Slager, Christopher C. Oakes

Blood (2024) 143 (17): 1752–1757.

https://doi.org/10.1182/blood.2023022180

Published: 2024

Includes: Supplemental data

Journal Articles

Ibrutinib-based therapy reinvigorates CD8 + T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

Despoina Papazoglou, Xin Victoria Wang, Tait D. Shanafelt, Connie E. Lesnick, Nikolaos Ioannou, Giulia De Rossi, Sylvia Herter, Marina Bacac, Christian Klein, Martin S. Tallman, Neil E. Kay, Alan G. Ramsay

Blood (2024) 143 (1): 57–63.

https://doi.org/10.1182/blood.2023020554

Published: 2024

Includes: Supplemental data

Journal Articles

Targeted Agents in Chronic Lymphocytic Leukemia (CLL): Advancements in Overall Survival Outcomes?

Stefano Molica, Tait D. Shanafelt, David Allsup, Diana Giannarelli

Blood (2023) 142 (Supplement 1): 4647.

https://doi.org/10.1182/blood-2023-180699

Published: 2023

Journal Articles

PD-1 Expression in Lymphoma Cells Mediates Cellular Proliferation By Engaging Phosphatase SHP-1/SHP-2

Blood (2023) 142 (Supplement 1): 3261.

https://doi.org/10.1182/blood-2023-177755

Published: 2023

Journal Articles

Longitudinal Analysis of Patient Reported Quality of Life in Newly Diagnosed Chronic Lymphocytic Leukemia Stratified By Initial Management Strategy: A Multi-Institutional Prospective Cohort Study

Amber Koehler, Brie N. Noble, Timothy G. Call, Sameer A. Parikh, Tait D. Shanafelt, Mazie Tsang, Côme Bommier, Kari G. Rabe, Christopher Strouse, Carrie Thompson, Paul J. Hampel, Kathleen Yost, Melissa C. Larson, Susan L. Slager, Brian K. Link, James R. Cerhan, Amylou Constance Dueck

Blood (2023) 142 (Supplement 1): 498.

https://doi.org/10.1182/blood-2023-187268

Published: 2023

Journal Articles

Mosaic Chromosomal Alterations and Monoclonal B-Cell Lymphocytosis: Relationship and Risk of Hematologic Malignancies

Rosalie Griffin, Aswin Sekar, Sameer A. Parikh, Giulio Genovese, Dennis P. Robinson, Aaron D. Norman, Janet E. Olson, Kari G. Rabe, Nicholas J. Boddicker, Paul J. Hampel, Neil E. Kay, Timothy G. Call, James R. Cerhan, Esteban Braggio, Curtis A. Hanson, Caline M. Vachon, Tait D. Shanafelt, Benjamin L. Ebert, Susan L. Slager

Blood (2023) 142 (Supplement 1): 2690.

https://doi.org/10.1182/blood-2023-184696

Published: 2023

Journal Articles

Progression and survival of MBL: a screening study of 10 139 individuals

Susan L. Slager, Sameer A. Parikh, Sara J. Achenbach, Aaron D. Norman, Kari G. Rabe, Nicholas J. Boddicker, Janet E. Olson, Geffen Kleinstern, Connie E. Lesnick, Timothy G. Call, James R. Cerhan, Celine M. Vachon, Neil E. Kay, Esteban Braggio, Curtis A. Hanson, Tait D. Shanafelt

Blood (2022) 140 (15): 1702–1709.

https://doi.org/10.1182/blood.2022016279

Published: 2022

Includes: Supplemental data

Journal Articles

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Blood (2022) 140 (2): 112–120.

https://doi.org/10.1182/blood.2021014960

Published: 2022

Includes: Supplemental data

Journal Articles

Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib

Blood (2022) 139 (14): 2252–2256.

https://doi.org/10.1182/blood.2021013926

Published: 2022

Includes: Supplemental data

Journal Articles

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Blood (2021) 138 (26): 2810–2827.

https://doi.org/10.1182/blood.2020010146

Published: 2021

Includes: Supplemental data

Journal Articles

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL

Sameer A. Parikh, Kari G. Rabe, Neil E. Kay, Timothy G. Call, Wei Ding, Jose F. Leis, Saad S. Kenderian, Eli Muchtar, Yucai Wang, Amber B. Koehler, Susan M. Schwager, Connie E. Lesnick, Geffen Kleinstern, Daniel Van Dyke, Curtis A. Hanson, Esteban Braggio, Susan L. Slager, Tait D. Shanafelt

Blood (2021) 138 (2): 149–159.

https://doi.org/10.1182/blood.2020009813

Published: 2021

Includes: Supplemental data

Journal Articles

Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families

Blood (2021) 137 (15): 2046–2056.

https://doi.org/10.1182/blood.2020006322

Published: 2021

Includes: Supplemental data

Journal Articles

Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy

Blood (2021) 137 (2): 216–231.

https://doi.org/10.1182/blood.2020006073

Published: 2021

Includes: Supplemental data

Journal Articles

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Blood (2019) 134 (Supplement_1): 33.

https://doi.org/10.1182/blood-2019-126824

Published: 2019

Journal Articles

Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis

Brian Giacopelli, BS, Kari G. Chaffee, MS, Yue-zhong Wu, MSc, John C. Byrd, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Christopher C. Oakes, PhD

Blood (2019) 134 (Supplement_1): 3022.

https://doi.org/10.1182/blood-2019-123564

Published: 2019

Journal Articles

Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia

Blood (2019) 134 (8): 688–698.

https://doi.org/10.1182/blood.2019000490

Published: 2019

Includes: Supplemental data

Journal Articles

Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL)

Nicholas J Boddicker, PhD, Daniel R O'Brien, Esteban Braggio, PhD, Sara J. Achenbach, Kari G. Chaffee, MS, Aaron D. Norman, Celine M. Vachon, PhD, Brian Kabat, B.S., Timothy G. Call, MD, Sameer A. Parikh, MD, Jose F. Leis, MD PhD, Wei Ding, MD PhD, Eli Muchtar, MD, James R. Cerhan, MD PhD, Tait D. Shanafelt, MD, Neil E. Kay, MD, Neil E Caporaso, Susan L. Slager, PhD

Blood (2018) 132 (Supplement 1): 3116.

https://doi.org/10.1182/blood-2018-99-117044

Published: 2018

Journal Articles

Ibrutinib-Based Therapy Improves Anti-Tumor T Cell Killing Function Allowing Effective Pairing with Anti-PD-L1 Immunotherapy Compared to Traditional FCR Chemoimmunotherapy; Implications for Therapy and Correlative Immune Functional Data from the Phase III E1912 Trial

Despoina Papazoglou, BSc, Connie E. Lesnick, Victoria Wang, Neil E. Kay, MD, Tait D. Shanafelt, MD, Alan G. Ramsay, BSc,MSc,PhD

Blood (2018) 132 (Supplement 1): 236.

https://doi.org/10.1182/blood-2018-99-118333

Published: 2018

Journal Articles

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Blood (2018) 132 (Supplement 1): 4394.

https://doi.org/10.1182/blood-2018-99-112989

Published: 2018

Journal Articles

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Tait D. Shanafelt, MD, Victoria Wang, Neil E. Kay, MD, Curtis A. Hanson, MD, Susan M. O'Brien, MD, Jacqueline C Barrientos, MD, Harry P. Erba, MDPhD, Richard M. Stone, MD, Mark R. Litzow, MD, Martin S. Tallman, MD

Blood (2018) 132 (Supplement 1): LBA-4.

https://doi.org/10.1182/blood-2018-120779

Published: 2018

NARROW

Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature

Ibrutinib-based therapy reinvigorates CD8 + T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

Targeted Agents in Chronic Lymphocytic Leukemia (CLL): Advancements in Overall Survival Outcomes?

PD-1 Expression in Lymphoma Cells Mediates Cellular Proliferation By Engaging Phosphatase SHP-1/SHP-2

Longitudinal Analysis of Patient Reported Quality of Life in Newly Diagnosed Chronic Lymphocytic Leukemia Stratified By Initial Management Strategy: A Multi-Institutional Prospective Cohort Study

Mosaic Chromosomal Alterations and Monoclonal B-Cell Lymphocytosis: Relationship and Risk of Hematologic Malignancies

Progression and survival of MBL: a screening study of 10 139 individuals

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL

Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families

Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis

Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia

Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL)

Ibrutinib-Based Therapy Improves Anti-Tumor T Cell Killing Function Allowing Effective Pairing with Anti-PD-L1 Immunotherapy Compared to Traditional FCR Chemoimmunotherapy; Implications for Therapy and Correlative Immune Functional Data from the Phase III E1912 Trial

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only